ClinicalTrials.Veeva

Menu
C

CER San Juan | San Juan, Argentina

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Abemaciclib
LY2835219
Abiraterone
Palbociclib
Teriflunomide
Exemestane
Tamoxifen
Imlunestrant
Anastrozole
Letrozole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 16 total trials

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abemaciclib

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling
Breast Neoplasms
Drug: Anastrozole
Drug: Tamoxifen

The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoi...

Active, not recruiting
Joint Diseases
Arthritis
Drug: Peresolimab
Drug: Placebo

The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab i...

Enrolling
Clear Cell Renal Cell Carcinoma
Biological: Nivolumab
Biological: Nivolumab and rHuPH20

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk...

Active, not recruiting
HER2-Positive Primary Breast Cancer
Residual Invasive Breast Cancer
Drug: DS-8201a
Drug: T-DM1

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible parti...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Placebo
Drug: Fenebrutinib

This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth...

Active, not recruiting
Breast Neoplasm
Neoplasm Metastasis
Drug: Fulvestrant
Drug: Placebo

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early s...

Active, not recruiting
Breast Cancer
Drug: Standard Adjuvant Endocrine Therapy
Drug: Abemaciclib

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbocic...

Enrolling
Breast Cancer
Drug: Alpelisib
Drug: Fulvestrant

Trial sponsors

Lilly logo
Pfizer logo
Roche logo
Array BioPharma logo
B
Bristol-Myers Squibb (BMS) logo
C
Daiichi Sankyo logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems